drugset / Trial / NCT07252401

Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury

NCT07252401

Not yet recruiting 64 enrolled General Hospital of Shenyang Military Region
RandomizedParallel-groupOpen-labelTreatment

Summary

Acute gastrointestinal bleeding (AGIB) is a common complication in the decompensated stage of liver cirrhosis, of which approximately 70% is acute variceal bleeding (AVB) caused by portal hypertension. Existing evidence suggests that both terlipressin and somatostatin can be used to control AVB in cirrhotic patients, but terlipressin may be the first-line treatment for cirrhotic patients with AGIB complicated by acute kidney injury (AKI). Herein, a multicenter randomized controlled trial (RCT) has been designed to compare the efficacy of terlipressin and somatostatin in the treatment of cirrhotic patients with AGIB complicated by AKI.

Timeline

Start
2025-12-25
Primary completion
2028-03-31
Completion
2028-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Somatostatin Traditional medicine (herbal / TCM) 3 mg Intravenous
Subject Terlipressin Peptide 2 mg Intravenous
Subject Terlipressin Peptide 4 mg Intravenous

Indications